Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Christopher T Su, MD, Liying Chen, MS, Jason Chen, MD, Brian Parkin, MD, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica Campagnaro, MD, Josh Vo, PhD, Dan Robinson, PhD, Yi-Mi Wu, PhD, Moshe Talpaz, MD, Jennifer Yesil, MSc, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MDPhD, Veerabhadran Baladandayuthapani, PhD, J Christine Ye, MDMSc

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134558

Published: 2020

Journal Articles

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

Naveen Pemmaraju, MD, Vikas Gupta, MD FRCP, FRCPath, Haris Ali, MD, Abdulraheem Yacoub, MD, Eunice S. Wang, MD, Sangmin Lee, MD, Gary J. Schiller, MD, Christopher Brooks, PhD, Nicole Rupprecht, MS, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Moshe Talpaz, MD, Minakshi S. Taparia, MBBS, Tariq I. Mughal, MD FRCP, Srdan Verstovsek, MD PhD, Joseph D. Khoury, MD, Mrinal M. Patnaik, MDMBBS

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137572

Published: 2020

Journal Articles

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-138752

Published: 2020

Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135883

Published: 2020

Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-133922

Published: 2020

Journal Articles

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Blood (2020) 136 (Supplement 1): 47–50.

https://doi.org/10.1182/blood-2020-139677

Published: 2020

Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2207.

https://doi.org/10.1182/blood-2019-129386

Published: 2019

Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 2670.

https://doi.org/10.1182/blood-2019-131949

Published: 2019

Journal Articles

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Aaron T. Gerds, MD MS, Michael R. Savona, MD, Bart L. Scott, MD, Moshe Talpaz, MD, Miklos Egyed, Claire N Harrison, Professor, Abdulraheem Yacoub, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Jennifer O'Sullivan, Sarah A Buckley, MD, Diane R. Mould, PhD, Shanthakumar Tyavanagimatt, PhD, Jennifer A. Smith, PhD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 667.

https://doi.org/10.1182/blood-2019-129293

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, MD PhD, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Jun Zhang, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 668.

https://doi.org/10.1182/blood-2019-129288

Published: 2019

Journal Articles

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 670.

https://doi.org/10.1182/blood-2019-127119

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison, Professor

Blood (2019) 134 (Supplement_1): 704.

https://doi.org/10.1182/blood-2019-129020

Published: 2019

Journal Articles

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3936.

https://doi.org/10.1182/blood-2019-131759

Published: 2019

Journal Articles

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

J Christine Ye, MDMSc, Liying Chen, Jason Chen, MD, Brian Parkin, Avery Polk, Malathi Kandarpa, PhD, Craig E. Cole, MD, Erica L. Campagnaro, MD, Dan Robinson, PhD, Yi-Mi Wu, Moshe Talpaz, MD, Jennifer Yesil, Daniel Auclair, P. Leif Bergsagel, MD, Arul Chinnaiyan, MD, Veerabhadran Baladandayuthapani

Blood (2019) 134 (Supplement_1): 4360.

https://doi.org/10.1182/blood-2019-124135

Published: 2019

Journal Articles

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Malathi Kandarpa, PhD, Kristen Pettit, MD, Tingting Qin, PhD, Yi-Mi Wu, PhD, Dan Robinson, PhD, Maureen Sartor, PhD, Arul Chinnaiyan, MD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 4212.

https://doi.org/10.1182/blood-2019-128301

Published: 2019

Journal Articles

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Ruben A. Mesa, MD, Moshe Talpaz, MD, Jean-Jacques Kiladjian, MD PhD, Claire N Harrison, Professor, Srdan Verstovsek, MD PhD, Sarah A Buckley, MD, Karisse Roman-Torres, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 4195.

https://doi.org/10.1182/blood-2019-124129

Published: 2019

Journal Articles

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Naveen Pemmaraju, MD, Krishna Gundabolu, MBBS, Kristen Pettit, MD, Moshe Talpaz, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Peter Eisenberg, MD, Hagop Youssoufian, MD, Susan Duggan, RN, MBA, Barbara Wallner, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4178.

https://doi.org/10.1182/blood-2019-130310

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Juan Shen, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 4165.

https://doi.org/10.1182/blood-2019-130069

Published: 2019

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

NARROW

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients

Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only